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Abstract
Background: The aim of this paper is to contribute to the discussion on how to approach patients taking new
orally administered anticoagulants (NOAs) dabigatran etexilate (a direct thrombin inhibitor), rivaroxaban and
apixaban (factor Xa inhibitors), before, during and after dental treatment in light of the more recent knowledges.
Discussion: In dentistry and oral surgery, the major concerns in treatment of patients taking direct thrombin
inhibitors and factor Xa inhibitors is the risk of haemorrhage and the absence of a specific reversal agent. The
degree of renal function, the complexity of the surgical procedure and the patient’s risk of bleeding due to other
concomitant causes, are the most important factors to consider during surgical dental treatment of patients taking
NOAs. For patients requiring simple dental extraction or minor oral surgery procedures, interruption of NOA is not
generally necessary, while an higher control of bleeding and discontinuation of the drug (at least 24 h) should be
requested before invasive surgical procedures, depending on renal functionality.
Summary: The clinician has to consider that the number of patients taking NOAs is rapidly increasing. Since
available data are not sufficient to establish an evidence-based dental management, the dentist must use caution
and attention when treating patients taking dabigatran, rivaroxaban and apixaban.
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Background
In the last few years, new orally administered anticoagu-
lants drugs (NOA) have been introduced in clinical prac-
tice for patients affected by various diseases and medical
conditions that require use of extended-duration anti-
coagulant therapy (prophylaxis and treatment of
pulmonary embolism and venous thrombosis, including
prophylaxis after orthopaedic surgery; prophylaxis and
treatment of thromboembolic complications associated
with atrial fibrillation and/or prosthetic valves replace-
ment; reduction of the risk of death, reinfarction and
thromboembolic events after myocardial infarction) [1].
Similarly to subcutaneous or intravenously administered
low-molecular-weight heparin (LMWH) and in contrast
to coumarin derivatives (warfarin and acenocoumarol),
these new medications interfere with very specific steps
of the coagulation cascade. Three types of NOAs have
recently been approved for use in the USA and in sev-
eral European countries, including Italy. These are dabi-
gatran etexilate, which acts as a direct thrombin
inhibitor (DTI), rivaroxaban and apixaban that work as
factor Xa inhibitors (FXaI). A fourth one FXaI, edoxa-
ban, obtained the recent approval of the European Medi-
cines Agency in Europe (April 2015, 23th) [2].
Advantages of dabigatran, rivaroxaban, apixaban and
edoxaban have to be researched in their capacity to pro-
vide a stable anticoagulation at a fixed dose without the
necessity to monitor the coagulation with routine la-
boratory exams (INR). They have a relatively rapid onset
and reach peak concentration in few hours [3]. Further-
more, unlike vitamin K antagonists, they show a wide
therapeutic margin, low drug- to- drug interactions and
no significant food interactions [1, 4].
The progressive diffusion of NOAs has a direct reper-
cussion on different dentistry specialties particularly in a
surgical context. Because of their relatively recent
* Correspondence: f.costantinides@fmc.units.it
1School of Specialization in Oral Surgery, Department of Medical, Surgical
and Health Sciences, University of Trieste, Trieste, Italy
Full list of author information is available at the end of the article
© 2016 Costantinides et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Costantinides et al. BMC Oral Health  (2016) 16:5 
DOI 10.1186/s12903-016-0170-7
introduction, specific studies regarding dental treatment
of patients taking NOAs are available in literature only
from 2012. No data exist regarding dental management
of patients treated with edoxaban. The aim of this paper
is to contribute to the discussion on how to approach
patients taking dabigatran, rivaroxaban or apixaban,
before, during and after dental treatment in light of the
more recent knowledges. For this purpose, a compre-
hensive search of the literature carried out through
PubMed (www.ncbi.nlm.nih.gov/pubmed) Pubmed Cen-
tral (http://www.ncbi.nlm.nih.gov/pmc/), Medline (http://
www.nlm.nih.gov/bsd/pmresources.html) and Cochrane
databases (http://www.cochranelibrary.com/), was per-
formed from inceptions to the last access in August 2015.
“Dabigatran”, “Rivaroxaban”, “Apixaban”, “Anticoagu-
lants”, “Dental”, “Oral”, “Surgery”, combined with the
Boolean operator ‘AND’ were used as search algorithm.
Studies that provided general and specific information on
NOAs in a dental context have been identified and
selected.
Discussion
Dabigatran etexilate (Pradaxa®)
Dabigatran etexilate is a specific, reversible DTI that,
after oral administration, is rapidly absorbed and con-
verted in its active form, dabigatran, through esterase-
catalyzed hydrolysis in plasma. Mechanism of action of
dabigatran is to bind with the active site on free and
clot-bound thrombin (factor IIa) so it cannot transform
fibrinogen into fibrin [5]. It has a rapid onset of action
with a peak plasma concentration at 0.5–4 h. The half –
life elimination is 12–14 h in healthy patients, 14–17 h
in elderly and up to 27 h in patient with severe renal
dysfunction (creatinine clearance <15–30 ml/min) [6].
Dabigatran is not a substrate of the hepatic cytochrome
P-450. The efficacy of dabigatran has been firstly
assessed by the RE-LY trial in 2009 [7]. Results showed
that, on a total of 18113 patients affected by atrial fibril-
lation recruited for the study, a dabigatran dose of
150 mg twice daily was associated to lower rates of
stroke and systemic embolism but similar rates of major
bleeding when compared with warfarin assumption. At a
110 mg twice daily, dabigatran showed similar rates of
stroke and systemic embolism when compare with war-
farin but with significantly lower cases of major bleeding.
The most important finding was that the rate of
hemorrhagic stroke with both doses of dabigatran was
less than one-third that of warfarin, without any reduc-
tion in the efficacy against ischemic stroke [7].
Although the prescription cost of dabigatran is signifi-
cantly higher than that of warfarin, the overall cost to
the health care system seems to be more cost-effective
than warfarin [8].
Monitoring of dabigatran is generally unnecessary;
however, in case of emergency, the thrombin clotting
time (TT) and the ecarin clotting time (ECT) are the
most sensitive tests for quantifying anticoagulation rate.
The activated partial thromboplastin time (aPTT) is less
sensitive, especially for higher doses of dabigatran but
anyway recommended in case of emergency situation
owing to its broad availability [9, 10]. The INR test is in-
sensitive to the activity of this drug and might not be el-
evated in patients taking dabigatran [11].
For patients who experience minor bleeding events,
the delaying of the next dose or the discontinuation
should be indicated although this choice has to be evalu-
ated with prudence considering the possible risk of is-
chemic events [12]. For moderate or severe bleeding,
treatments include mechanical compression, surgical
intervention, fluid replacement, hemodynamic support,
oral charcoal application (for recent ingestion of dabiga-
tran) and haemodialysis. For life-threatening bleeding,
treatment includes administration of prothrombin com-
plex concentrates or charcoal and supportive measures
[13] although recent investigations showed no effect of
prothrombin complex concentrates on aPTT, TT and
ECT [12]. In October, 2015, the U.S. Food and Drug
Administration approved idarucizumab, a monoclonal
antibody fragment (Praxbind®, Boehringer Ingelheim
Pharmaceuticals, Inc., Germany) for the treatment of pa-
tients taking dabigatran etexilate when reversal of the
anticoagulant effects of dabigatran is needed for emer-
gency surgery/urgent procedures, or in life-threatening
or uncontrolled bleeding [14]. Idarucizumab rapidly and
completely reversed (within minutes) the anticoagulant
activity of dabigatran in 88 to 98 % of patients in an ini-
tial clinical study [15]. The approval of idarucizumab will
substantially influence the approach to haemorrhagic
complications related to dabigatran probably solving the
concerns that had been raised for the lack of a proven
reversal strategy with respect to severe bleeding events
in patients taking this NOA [12, 16].
Discontinuing anticoagulants, including dabigatran, for
elective surgery or invasive procedures places patients at
an increased risk of stroke and, if discontinuation is ne-
cessary, dabigatran should be restarted as soon as pos-
sible [17].
Perioperative bleeding associated to dabigatran etexilate
In the RE-LY trial (dabigatran versus warfarin in the
treatment of atrial fibrillation), the rate of major bleed-
ing associated with an invasive procedure or surgery was
expressed as percentage [18]. Major bleeding was similar
with dabigatran 110 mg twice daily (3.8 %), dabigatran
150 mg twice daily (5.1 %), and warfarin (4.6 %). Bleed-
ing was greater in those undergoing urgent surgery
(18 %, 18 %, and 22 %, respectively). The risk of major
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bleeding was increased in those who received bridging
anticoagulation compared with those who did not, an ef-
fect that was seen both with dabigatran (major bleeding
with and without bridging, 6.5 % versus 1.8 %) and war-
farin (6.8 % versus 1.6 %) [19].
Perioperative thromboembolic risk associated to dabigatran
etexilate
Of the 4591 patients who underwent elective procedures
or surgery in the RE-LY trial, the perioperative thrombo-
embolic risk was 1.2 %, based on a composite endpoint
of stroke, cardiovascular death, and pulmonary embol-
ism. There were no differences in thromboembolic risk
with dabigatran versus warfarin, or with the high versus
the low dabigatran dose. However, urgent surgery was
associated with a higher risk of ischemic stroke or sys-
temic embolism than elective surgery (warfarin: 1.8 %
versus 0.4 %; dabigatran 150 mg twice daily: 1.4 % versus
0.4 %; dabigatran 110 mg twice daily: 2.8 % versus 0.3 %)
[18].
Dental consideration for patients taking dabigatran
The major concern in treatment of patients taking DTIs
is the risk of haemorrhage in dentistry and oral surgery
too. The recent approval of idarucizumab will help in
solving the concerns related to the absence of a specific
reversal agent for dabigatran. To date, there have been
no published studies on the incidence of bleeding events
among patients receiving dabigatran. However, several
studies demonstrated that the risk of haemorrhage for
patients taking DTIs is similar to those taking warfarin
when the INR value ranges between 2 and 3 (except for
gastrointestinal bleeding) [7, 18, 20]. For patients requir-
ing simple dental extraction or minor oral surgery pro-
cedures (as localized surgical extraction, localized
periodontal surgery, apicectomies, incisional biopsies or
excision of localized mucosal lesion), it can be assumed
that the risk is similar to that of patients taking vitamin
k antagonists and with an INR < 3 [12]. One of the first
rules to reduce the risk of bleeding, is to perform the
surgical procedures as late as possible after the most re-
cent assumption of dabigatran. After surgery, local
haemostatic measures such as suturing, gelatine sponge
or cellulose mesh, tranexamic acid mouth rinse (twice
daily for 2–5 days) may help in controlling postoperative
bleeding [21, 22]. Elective invasive surgical procedures
as multiple surgical extractions, removal of extensive
intraosseous lesions or maxillofacial surgery, should re-
quest an higher control of bleeding and even the deci-
sion of discontinuation of the drug because some dental
patients may have a higher risk of bleeding when taking
dabigatran [6]. A patient with high bleeding risk in a
surgical context is a subject that could develop
hemorrhagic complications (also life-threatening) that
need important haemostatic interventions (like tissue or
vascular sutures, use of pro-coagulants or reversal
agents). Several factors concur in the assessment of
bleeding risk and these are patient-dependent or
surgery-dependent. Patient-dependent factors are age,
renal functionality, congenital or acquired alterations of
the coagulation, assumption of antiplatelet or anticoagu-
lant drugs (i.e. patients older than 75 years and taking
acetylsalicylic acid, long term NSAIDs or clopidogrel or
prasugrel) [23]. Surgery-dependent factors are correlated
to the invasiveness and difficulty of the surgery. To as-
sess the risk of bleeding, patient-dependent factors and
surgery-dependent factors must be considered together.
In this sense an accurate anamnesis and surgical plan-
ning are extremely important to intercept these high-
risk categories. Actually, the best available protocol
regarding discontinuation of dabigatran in elective sur-
gery is that proposed by van Ryn et al. [9]. It takes into
account the degree of renal function, the complexity of
the surgical procedure and the patient’s risk of bleeding
due to other concomitant causes (Table 1). Additionally,
TT or aPTT performed 6 to 12 h prior to surgical treat-
ment can indicate, when normal, if the anticoagulant ef-
fect of dabigatran has resolved [6].
Dabigatran should be restarted once a stable clot has
formed, usually within 24–48 h following surgery, be-
cause of the rapid onset of this drug [1].
Anyway, all the modifications of the therapy with dabi-
gatran have to be discussed with the patient’s physician
in terms of risks-benefit to optimize the surgical treat-
ment without increasing the risk of thromboembolism.
In patients needing a maintenance of anticoagulation
during extensive major oral surgery, a switch to LMWH
should be considered [12]. Furthermore, in the postoper-
ative phase, attention has to be paid to the administra-
tion of analgesics. Although dabigatran does not directly
interact with NSAIDs, both increase the risk of bleeding
[12]. For this reason, prescription of NSAIDs should be
made with caution, preferring alternative drugs for pain
Table 1 Guide to discontinuation of dabigatran before elective
surgery; indications are matched for renal function and risk of
bleeding (van Ryn et al. 2010) [9]
Cretinine
clearance
(ml/min)
Time of discontinuation
before surgery for standard
risk of bleeding
Time of discontinuation
before surgery for high risk
of bleedinga
>80 24 h 2–4 days
>50 to≤ 80 24 h 2–4 days
>30 to≤ 50 ≥48 h 4 days
≤30b 2–5 days 5 days
aDeterminants of bleeding risk are: type of surgery (cardiac, neural, abdominal,
surgery involving major organs or requiring complete haemostasis), advanced
age, comorbidities (i.e. major cardiac, respiratory, liver diseases) and
concomitant use of antiplatelet therapy
bDabigatran controindicated
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management. Paracetamol or opioid medications are
safer alternatives for patients taking dabigatran [12].
Dabigatran acts as a substrate of P- glycoprotein 1
(P-gp 1), an important protein of the cell membrane
that pumps many foreign substances out of cells.
Concomitant assumption of strong P-gp 1 inducers
like rifampicin, dexamethasone and carbamazepine,
has been reported to significantly decrease the plasma
concentration-versus time curve and peak serum con-
centration of dabigatran. For this reason, these drugs
are not recommended in patients taking DTIs [1]. A
single dose of 400 mg of ketoconazole, a P-gp 1 in-
hibitor, was reported to increase the peak plasma
concentration of dabigatran to 135 % while concomi-
tant therapy with clarithromycin, a moderate P-gp 1
inhibitor, has substantially no effects on dabigatran
concentrations. The administration of P-gp 1 inhibi-
tors like ketoconazole (and possibly itraconazole,
erythromycin, clarithromycin) should be avoided or, if
necessary, a reduced dose of dabigatran may be indi-
cated [1].
Rivaroxaban (Xarelto®)
Rivaroxaban is an orally administered selective, revers-
ible direct FXaI that binds with the part of factor XaI
that catalyzes the activation of prothrombin (factor II)
[1]. Rivaroxaban can inhibit free factor Xa but also clot-
bound factor Xa and factor Xa bound to the prothrom-
binase complex [5]. The drug shows a rapid onset and
reaches the peak plasma concentration in 2.5–4 h after
oral administration (once daily). The half-life is 5.7–
9.2 h (up to 12–13 h in patients older than 75 years) and
approximately 51 % of rivaroxaban undergoes metabolic
degradation without involving cytochrome P-450. FXaIs,
including rivaroxaban, slightly prolong prothrombin
time (PT) and aPTT. No routine monitoring of rivaroxa-
ban is generally required however, in case of an emer-
gency, anti factor Xa is reported as the most accurate
measurement of anticoagulation.
Rivaroxaban is indicated in the prevention of ven-
ous thromboembolism in adults subjected to elective
hip or knee replacement surgery, in the treatment of
deep venous thrombosis (DVT) and pulmonary em-
bolism following DVT in adults patients [4]. The effi-
cacy of rivaroxaban in comparison with warfarin, was
tested in the ROCKET-AF study, a large clinical trial
that assessed the effectiveness of the drugs in reduc-
tion of ischemic stroke or systemic embolism in pa-
tient affected by atrial fibrillation [24]. Recent meta-
analysis and systematic reviews showed that FXaI sig-
nificantly reduces the number of strokes and systemic
embolic events compared with warfarin in patients
with atrial fibrillation. FXaI also seems to reduce the
number of major bleedings and intracranial haemor-
rhages compared with warfarin [25, 26].
Rivaroxaban has not a specific antidote [1] although
some studies suggest the use of recombinant factor VIIa
or active concentrate prothrombin complex to antagon-
izing the anticoagulant effect [27]. Recently, a modified
form of factor Xa is being studied as a potential antidote
for factor Xa inhibitors. This recombinant protein (r-
Antidote, PRT064445, Portola Pharmaceuticals) is cur-
rently undergoing clinical trials for effectiveness of rever-
sal of the effects of oral factor Xa inhibitors (rivaroxaban
and apixaban) [28].
Perioperative bleeding associated to rivaroxaban
Minor bleeding events have been observed in 4–7 % of
patients, while < 1–2 % experienced major bleeding
events [29].
In the ROCKET AF trial (rivaroxaban versus warfarin
for atrial fibrillation), the rate of major bleeding associ-
ated with an invasive procedure or surgery was 2.3 %
[30]. Bleeding was similar between the two anticoagu-
lants, and between patients who received bridging antic-
oagulation and those who did not.
Perioperative thromboembolic risk associated to
rivaroxaban
In the ROCKET AF trial, a randomized, double-blind,
double-dummy study of rivaroxaban and warfarin in
non-valvular atrial fibrillation, baseline characteristics,
management, and outcomes, including stroke, non-
central nervous system systemic embolism, death, myo-
cardial infarction, and bleeding, were reported in partici-
pants who experienced temporary interruption (TI, 3–30
days) for any reason [30]. The at-risk period for out-
comes associated with TI was from TI start to 30 days
after resumption of study drug. In 14236 participants
who received at least 1 dose of study drug, 4692 (33 %)
experienced TI. Participants with TI were similar to the
overall ROCKET AF population in regard to baseline
clinical characteristics. Only 6 % (n = 483) of TI inci-
dences involved bridging therapy. Stroke/systemic em-
bolism rates during the at-risk period were similar in
rivaroxaban-treated and warfarin-treated participants
(0.30 % versus 0.41 % per 30 days).
Rivaroxaban is the only NAO, with a study that con-
sidered interruption of treatment, for apixaban and dabi-
gatran further studies are needed.
Dental consideration for patients taking rivaroxaban
To date, there are no clinical trials supporting specific
measures in the event of haemorrhage in dental patients
taking rivaroxaban. The most current informations sug-
gest that interruption of rivaroxaban is not required for
simple surgery like dental extraction [1, 31]. In general,
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the indications given for dabigatran are also applicable
to rivaroxaban. Therefore, the drug can be normally ad-
ministered without discontinuation, for uncomplicated
extractions and other similar dental procedures in pa-
tients with normal renal functionality [6]. As dabigatran,
rivaroxaban should be discontinued at least 24 h before
oral and maxillofacial surgery in patients at risk of exces-
sive bleeding or impaired haemostasis [1]. Patients with
severe renal impairment may necessitate a period > 24 h
of discontinuation because they show a significant in-
crease in maximum plasma concentration and longer
half- life of rivaroxaban [1]. When discontinued, rivarox-
aban should not be restarted immediately after surgery,
but usually within 24–48 h due to its rapid onset [1]. As
for dabigatran, the decision of discontinuation has to be
carefully discussed with the patients’s physician to avoid
possible thrombo-embolic complications.
PT and APTT are not clinically useful in assessing the
anticoagulant effect before oral surgery in patients taking
rivaroxaban [1, 17].
When prescribing medical therapy for the treatment
of oral and dental pathologies, clinician has to remember
that two third of rivaroxaban is metabolized by cyto-
chrome P-450 system (in particular by cytochrome
P3A4) and it is also a substrate of P-gp transporters [6].
Concomitant use of strong CYP3A4 and P-gp inhibitors
such as ketoconazole, itraconazole, voriconazol and
posaconazole can increase serum concentration of
rivaroxaban and should be avoided. Eventually, only flu-
conazole can be coadministered with caution [6]. Clari-
thromycin, a strong CYP3A4 inhibitor and a moderate
P-gp inhibitor, slightly increases peak serum concentra-
tion of rivaroxaban when administered with a dose of
500 mg twice daily. Also erythromycin (a moderate
CYP3A4 and P-gp inducer) does not lead to a clinically
significant increase of serum concentration of rivaroxa-
ban when taken at a dose of 500 mg, times per day [1].
Conversely, rifampicin, a CYP3A4 inducer, may increase
the metabolism of rivaroxaban decreasing the level of
anticoagulation [6].
There are no reports of interaction between rivaroxa-
ban and amoxicillin, cephalexin, cefazolin, ampicillin or
clindamycin [17]. Therefore, none of these antibiotics
can be used safely.
No clinically relevant interaction has been observed
between rivaroxaban and NSAIDs, although a study by
Kubitza et al. [32] showed a significant increase in bleed-
ing time for patients taking rivaroxaban and naproxen in
comparison of those taking rivaroxaban alone. However,
the increased bleeding time resulted not clinically rele-
vant. It has also been observed that patients co-
medicated with opioid drugs experienced higher major
or non-major clinically relevant post-surgical bleeding
compared with those co-medicated with NSAIDs. Based
on these informations, prudence is needed when using
NSAIDs and opioid drugs in patients taking rivaroxaban.
A careful monitoring of the entity of bleeding is indi-
cated in these patients especially during and after surgi-
cal dental procedure [1].
Apixaban (Eliquis®)
Apixaban is the most recently introduced direct anti-
coagulant. It is a reversible orally administered FXaI with
the same therapeutic indications of dabigatran and rivar-
oxaban. After intake, the peak plasma concentration is
reached in about 1–3 h with an oral bioavailability of ap-
proximately 60 %. The half-life of the drug is about 12 h
and it is excreted almost totally in bile [4]. As rivaroxa-
ban, no specific reversal agent exists for apixaban. In
case of emergency situations, recombinant factor VIIa,
recombinant factor Xa or activated thrombin complexes
can be used. In situations of normal bleeding, the delay
or discontinuation of the next dose can be sufficient to
resolve bleeding. However, few data are available for cor-
rect management of apixaban in case of haemorrhage
and further studies are needed in this respect.
Perioperative Bleeding associated to apixaban
Data of ARISTOTLE trial (apixaban versus warfarin for
atrial fibrillation) [33] showed that the rate of major
bleeding associated with an invasive procedure or sur-
gery was 1.8 %. Major bleeding was similar in those re-
ceiving apixaban or warfarin (1.6 % versus 1.9 %), and in
those who continued or interrupted apixaban (1.6 % ver-
sus 1.7 %). In the warfarin arm, the rate of major bleed-
ing was 3.0 % in those who continued warfarin versus
1.3 % in those who interrupted it. Many of the proce-
dures were low risk (dental extraction, ophthalmologic
surgery, colonoscopy or upper endoscopy).
Perioperative thromboembolic risk associated to apixaban
During 9260 procedures performed on patients in the
ARISTOTLE trial, the perioperative thromboembolic
risk was 0.57 % for warfarin and 0.35 % for apixaban
[33].
Dental considerations for patients taking apixaban
Because apixaban is one of the most recently marketed
direct anticoagulant (2013), few data or guidelines are
available for management of dental patient taking this
drug. In general, the same indications used for dabigra-
tran and rivaroxaban can be valid. Actually, there is no
necessity to suspend apixaban before dental surgery in
patients with no comorbidities for increased bleeding
but further studies are needed in this respect. Similarly
to rivaroxaban, administration of potent CYP3A4 and P-
gp inhibitors are contraindicated [4].
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Table 2 Principal characteristics of new oral anticoagulants (NOAs)
NOAs Class Indications Dosage Time to peak
plasma concentration
Half life Routes of
elimination
Monitoring of
coagulation
Dabigatran
etexilate
Direct
thrombin
inhibitor
Prevention of cerebrovascular complications in non-valvular
atrial fibrillation; hip and knee replacement surgery;
venous thromboembolism prophylaxis and management
110 mg-
150 mg
twice daily
2–4 h 12–14 h; 14–17 h in elderly; 15–18 h in
moderate renal impairment; up to 28 h in
advanced renal impairment
80 % renal,
20 % hepatic
Not needed
Rivaroxaban Direct
inhibitor
of factor
Xa
Prevention of cerebrovascular complications in non-valvular
atrial fibrillation; venous thromboembolism prophylaxis and
management
20 mg
daily
2.5–4 h 5–10 h; 12–13 h in patients > 75 years 66 % renal,
28 % in feces
Not needed
Apixaban Direct
inhibitor
of factor
Xa
Prevention of cerebrovascular complications in non-valvular
atrial fibrillation; venous thromboembolism prophylaxis and
management
5 mg
twice daily
1–3 h 10–14 h 25 % renal,
55 % intestinal,
remnant
hepatic
Not needed
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Final considerations
Summary of main characteristics of dabigratran etexilate,
rivaroxaban and apixaban is shown in Table 2. Table 3
summarizes the more recent guidelines for dental man-
agement of patients taking NOAs.
The analysis of the literature showed that the interin-
dividual pharmacokinetic variability of NOAs is large.
The four drugs that are most advanced in their clinical
development and regulatory proceedings (dabigatran
etexilate, rivaroxaban, apixaban and edoxaban) differ in
their rate and extent of digestive adsorption and in the
mechanisms and rate of elimination, predominantly
renal or hepatobiliary.
However, the absorption, distribution, metabolism and
elimination of these drugs are governed by many vari-
ables: liver and/or renal function, sex, weight, age, gen-
etic polymorphisms of enzyme or efflux systems, drug-
drug interference, etc. It follows that for a given patient,
the residual concentration at a given time after halting
treatment cannot be accurately calculated from the aver-
age values of the pharmacokinetics in the target
population.
Once the thromboembolic and bleeding risks have
been estimated, a decision can be made about whether
the anticoagulant should be interrupted or continued.
Data comparing the relative benefits of continuing antic-
oagulation versus interrupting an anticoagulant are lim-
ited, and decisions that balance thromboembolic and
bleeding risks must be made on a case-by-case basis. No
scoring system can substitute for clinical judgment in
this decision-making.
Dental procedures are generally considered to confer a
low risk of bleeding, and anticoagulation can be contin-
ued in most patients during these procedures. The evi-
dence of continuing anticoagulation during selected low
bleeding risk surgery comes from patients receiving war-
farin with an INR in the therapeutic range [34, 35]. Con-
versely, the anticoagulant should be discontinued if the
surgical bleeding risk is considered high (i.e. multiple ex-
tractions >5, surgery lasting more than 45 min, head and
neck cancer, extensive oral and maxillofacial surgery in
patients with comorbidities) [4, 36]. If a concomitant
very high or high thromboembolic risk exists, the period
without anticoagulation should be limited to the shortest
possible interval. Unlike patients taking vitamin K antag-
onist, bridging with LMWH could be not required for
those with very high or high thromboembolic risk who
are receiving a DTI or FXaIs, in light of the shorter half-
Table 3 Summary of the more recent guidelines for dental management of patients taking NOAs
Author Type of NOA Minor surgical procedures (low-medium risk)a Major surgical procedures and/or co-morbidities
(high risk)b
Firriolo FJ
and Hupp
WS, 2012 [1]
Dabigatran For dental procedure that involve bleeding: do not
discontinue the daily dose in patient with normal renal
function and without other risk for impaired haemostasis
For oral and maxillofacial surgical procedures with
possible complications for excessive bleeding and/or
impaired haemostasis: discontinue dabigatran ≥ 24 h
before surgery or longer depending on renal impairment
and bleeding risk (Table 1).
Restart the drug at least 24 h postoperatively.
Rivaroxaban For dental procedure that involve bleeding: do not
discontinue the daily dose in patient with normal renal
function and without other risk for impaired haemostasis
For oral and maxillofacial surgical procedures with
possible complications for excessive bleeding and/or
impaired haemostasis: discontinue rivaroxaban ≥ 24 h
before surgery or longer depending on renal impairment
and bleeding risk (Table 1).
Restart the drug at least 24 h postoperatively.
Davis C et al.,
2013 [12]
Dabigatran Perform surgery as long as possible after last doseUse
local haemostatic measures
Discontinue 2–3 half –lives before surgeryAdjust time of
discontinuation for renal impairment
Hong CH
and Islam I,
2013 [36]
Dabigatran,
Rivaroxaban,
Apixaban
Do not change administrationUse local haemostatic
measures
Suspend administration 24 h before surgery and restart
drugs after complete haemostasis is achieved at least
after 24 h post-operatively
Breik O et al.,
2013 [37]
Dabigatran Do not discontinue the drugUse local haemostatic
measures (mechanical pressure, suturing an local
haemostats)
In consultation with the patient’s physician, consider
discontinuing the drug 24 h before procedure (or≥ 48 h
depending on degree of renal impairment) or changing
to another anticoagulant preoperatively.Consider
checking aPTT preoperatively
Restart dabigatran 24–48 h after operation.
aLow-medium risk: local anaesthetic infiltration; simple single extraction; soft tissue biopsy ≤ 1 cm; supragingival prophylaxis; placement of rubber dam;
restorations; crown preparation; root canal therapy; prosthetic rehabilitation of implant; band and brackets removal; wire insertion. Medium risk: local anaesthesia
nerve block; multiple simple extractions ≤ 5 teeth; soft tissue biopsy 1–2.5 cm; placement of single implant; ultrasonic scaling; one to two quadrants (6–12 teeth)
deep subgingival scaling; localize periodontal surgery ≤ 5 teeth (Hong and Islam, 2013) [36]
bHigh risk: multiple extraction > 5 teeth; surgical extraction requiring periosteal flap and ostectomy; soft tissue biopsy > 2.5 cm; osseous biopsy; removal of torus;
placement of multiple implants; full mouth disinfection with deep subgingival cleaning; periodontal surgery > 5 teeth; endodontic surgery with osseous
manipulation (Hong and Islam, 2013) [36]. Co-morbidities: presence of renal impairment; advancing age; major cardiac, respiratory or liver diseases; concomitant
use of antiplatelet therapy (van Ryn et al., 2010) [9]
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lives of these agents and the recent introduction of DTI
reversal agent [12, 14].
NOAs are seeing increased use in Europe and USA,
thanks to their efficacy and benefits. However, few data
are still available regarding dental management of pa-
tients taking dabigatran, rivaroxaban, apixaban and
edoxaban. The lack of data with regards to bleeding risk
in dental treatment is still a concern among clinicians.
For this reason, clinical prospective studies are strongly
encouraged to determine the perioperative risks after
oral surgical procedures and to define evidence-based
guidelines for dental management of patients taking
NOAs.
Summary
Dabigatran etexilate, rivaroxaban, apixaban and edoxa-
ban are four recently introduced drugs for the treatment
of patients affected by various diseases and medical con-
ditions that require use of extended-duration anticoagu-
lant therapy. These new oral anticoagulant agents
(NOAs) interfere with very specific steps of the coagula-
tion cascade: dabigatran etexilate acts as a direct throm-
bin inhibitor (DTI), rivaroxaban, apixaban and edoxaban
work as factor Xa inhibitors (FXaI). Since no specific re-
versal agents are available for these drugs (except for
dabigatran etexilate), surgical dental treatment of pa-
tients taking NOAs requires particular attention in light
of the bleeding risk associated to the procedure. Inter-
ruption of the NOA administration is generally not ne-
cessary for simple surgery as single dental extraction,
while suspension has to be considered for extensive sur-
gical treatments and/or in cases of patient’s comorbidi-
ties as renal impairment, advanced age or concomitant
anti-platelet therapies.
Although the number of patients treated with NOAs is
increasing, currently no established evidence-based
guidelines are still available in literature for dental man-
agement of this cohort of patients. For this reason, fur-
ther clinical prospective studies are needed to investigate
the bleeding risk and haemostasis associated to surgical
dental procedures.
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